Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for IBRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2014. Start Trial.
Date Value
June 30, 2026 357.37M
March 31, 2026 380.88M
December 31, 2025 242.82M
September 30, 2025 257.81M
June 30, 2025 153.66M
March 31, 2025 61.59M
December 31, 2024 149.81M
September 30, 2024 130.37M
June 30, 2024 217.98M
March 31, 2024 170.50M
December 31, 2023 266.46M
September 30, 2023 189.80M
June 30, 2023 45.95M
March 31, 2023 91.27M
December 31, 2022 107.18M
September 30, 2022 111.06M
June 30, 2022 82.94M
March 31, 2022 192.33M
December 31, 2021 317.12M
September 30, 2021 80.37M
June 30, 2021 103.93M
March 31, 2021 83.27M
December 31, 2020 66.21M
September 30, 2020 89.04M
Date Value
June 30, 2020 110.62M
March 31, 2020 40.22M
December 31, 2019 51.65M
September 30, 2019 66.06M
June 30, 2019 84.30M
March 31, 2019 99.75M
December 31, 2018 74.15M
September 30, 2018 84.03M
June 30, 2018 105.30M
March 31, 2018 121.79M
December 31, 2017 128.15M
September 30, 2017 152.27M
June 30, 2017 175.50M
March 31, 2017 190.97M
December 31, 2016 198.92M
September 30, 2016 209.26M
June 30, 2016 213.76M
March 31, 2016 221.76M
December 31, 2015 294.22M
September 30, 2015 358.62M
June 30, 2015 120.44M
March 31, 2015 49.85M
December 31, 2014 59.10M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Moderna, Inc. 5.138B
Sarepta Therapeutics, Inc. 788.49M
Arrowhead Pharmaceuticals, Inc. 1.602B
Oncolytics Biotech, Inc. 4.115M
Sangamo Therapeutics, Inc. 27.59M